Mariner
GALT icon

Mariner’s Galectin Therapeutics GALT Stock Holding History

Mariner’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.8K Sell
18,500
-1,312
-7% -$3.4K ﹤0.01% 3353
2026
Q1 		$55.3K Sell
19,812
-93
-0.5% -$283 ﹤0.01% 3411
2025
Q4 		$82.8K Sell
19,905
-7,666
-28% -$40.4K ﹤0.01% 3356
2025
Q3 		$117K Buy
27,571
+63
+0.2% +$237 ﹤0.01% 3325
2025
Q2 		$58K Buy
27,508
+1,092
+4% +$1.63K ﹤0.01% 3327
2025
Q1 		$32.2K Sell
26,416
-911
-3% -$1.28K ﹤0.01% 3337
2024
Q4 		$35.3K Buy
27,327
+742
+3% +$1.78K ﹤0.01% 3320
2024
Q3 		$73.1K Buy
26,585
+109
+0.4% +$268 ﹤0.01% 3139
2024
Q2 		$59.8K Sell
26,476
-1,902
-7% -$5.78K ﹤0.01% 3025
2024
Q1 		$67.8K Buy
28,378
+17,500
+161% +$33.1K ﹤0.01% 2992
2023
Q4 		$18.1K Hold
10,878
– – ﹤0.01% 3006
2023
Q3 		$20.9K Buy
10,878
+78
+0.7% +$128 ﹤0.01% 2841
2023
Q2 		$15.6K Hold
10,800
– – ﹤0.01% 2793
2023
Q1 		$23K Hold
10,800
– – ﹤0.01% 2718
2022
Q4 		$12K Sell
10,800
-567
-5% -$755 ﹤0.01% 2711
2022
Q3 		$19K Buy
+11,367
New +$21.2K ﹤0.01% 2380

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mariner's GALT Position: Q2 2026 in Review

Mariner reduced its Galectin Therapeutics (GALT) stake by 6.6% in Q2 2026, selling an estimated $3.4K and leaving 18,500 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3353.

Mariner first reported a position in GALT in Q3 2022 and has held it in 16 quarters since. The position peaked at $117K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Mariner held 18,500 shares of Galectin Therapeutics worth $85.8K as of Q2 2026.
  • Mariner sold 1,312 Galectin Therapeutics shares in Q2 2026, an estimated $3.4K.
  • Galectin Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3353 holding.
  • Mariner first reported a position in Galectin Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Mariner's Galectin Therapeutics position peaked at $117K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.